


## Cefroxadine

<b>Cat. No.:</b>	HY-107064
<b>CAS No.:</b>	51762-05-1
<b>Molecular Formula:</b>	C <sub>16</sub> H <sub>19</sub> N <sub>3</sub> O <sub>5</sub> S
<b>Molecular Weight:</b>	365.4
<b>Target:</b>	Bacterial; Antibiotic
<b>Pathway:</b>	Anti-infection
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Cefroxadine (CGP 9000) is an orally active cephalosporin antibiotic. Cefroxadine is more effective than cephalixin against <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> with MIC values of 3.13 and 1.56 µg/mL respectively with a concentration of 10 <sup>6</sup> µg/mL. Cefroxadine can be used for the research of infection <sup>[1]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	β-lactam								
<b>In Vitro</b>	Cefroxadine (10 <sup>6</sup> -10 <sup>8</sup> µg/mL; overnight) shows antibacterial activities against <i>S. aureus</i> , <i>E. coli</i> , <i>S. typhi</i> , <i>S. paratyphi</i> , <i>S. schottmuelleri</i> , <i>K. pneumoniae</i> and <i>P. mirabilis</i> with MIC values of 1.56, 3.31, 1.56, 1.56, 1.56, 1.56 and 6.25 µg/mL respectively with a concentration of 10 <sup>6</sup> µg/mL <sup>[1]</sup> . Cefroxadine (10 <sup>4</sup> -10 <sup>8</sup> µg/mL; overnight) shows antibacterial activities against 100 <i>E. coli</i> strains with MIC <sub>50</sub> and MIC <sub>75</sub> values of 4.8-11.5 µg/mL and 6-20 µg/mL, respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
<b>In Vivo</b>	Cefroxadine (0-30 mg/kg; p.o. 0 and 3 h after infection) shows a better effect than cephalixin in vivo <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Mice with <i>E. coli</i> ML4707 and <i>K. pneumoniae</i> GN6445 infection<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0-30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral gavage; 0-30 mg/kg; 0 and 3 h after infection</td> </tr> <tr> <td>Result:</td> <td>Showed a better effect than cephalixin in vivo with ED<sub>50</sub> values of 21.4 and 10.9 mg/kg for <i>E. coli</i> ML4707 and <i>K. pneumoniae</i> GN6445 in vivo.</td> </tr> </table>	Animal Model:	Mice with <i>E. coli</i> ML4707 and <i>K. pneumoniae</i> GN6445 infection <sup>[1]</sup>	Dosage:	0-30 mg/kg	Administration:	Oral gavage; 0-30 mg/kg; 0 and 3 h after infection	Result:	Showed a better effect than cephalixin in vivo with ED <sub>50</sub> values of 21.4 and 10.9 mg/kg for <i>E. coli</i> ML4707 and <i>K. pneumoniae</i> GN6445 in vivo.
Animal Model:	Mice with <i>E. coli</i> ML4707 and <i>K. pneumoniae</i> GN6445 infection <sup>[1]</sup>								
Dosage:	0-30 mg/kg								
Administration:	Oral gavage; 0-30 mg/kg; 0 and 3 h after infection								
Result:	Showed a better effect than cephalixin in vivo with ED <sub>50</sub> values of 21.4 and 10.9 mg/kg for <i>E. coli</i> ML4707 and <i>K. pneumoniae</i> GN6445 in vivo.								

### REFERENCES

[1]. Yasuda K, et al Cefroxadine (CGP-9000), an orally active cephalosporin. *Antimicrob Agents Chemother.* 1980 Jul;18(1):105-10.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA